Cubist Systematic Strategies’s Vertex Pharmaceuticals VRTX Stock Holding History

Cubist Systematic Strategies’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$9.28M	Sell	23,700 -3,300	-12%	-$1.38M	0.04%	608
2025 Q2	$12M	Buy	27,000 +5,000	+23%	+$2.3M	0.06%	510
2025 Q1	$10.7M	Buy	22,000 +8,100	+58%	+$3.77M	0.06%	453
2024 Q4	$5.6M	Buy	+13,900	New	+$6.44M	0.04%	770
2023 Q4	–	Sell	-21,900	Closed	-$7.62M	–	4157
2023 Q3	$7.62M	Buy	21,900 +8,600	+65%	+$3.01M	0.06%	516
2023 Q2	$4.68M	Buy	13,300 +12,500	+1,563%	+$4.21M	0.03%	884
2023 Q1	$252K	Sell	800 -23,800	-97%	-$7.14M	﹤0.01%	3087
2022 Q4	$7.1M	Sell	24,600 -11,200	-31%	-$3.41M	0.04%	729
2022 Q3	$10.4M	Buy	35,800 +18,700	+109%	+$5.38M	0.06%	450
2022 Q2	$4.82M	Buy	+17,100	New	+$4.58M	0.03%	1028

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Cubist Systematic Strategies's VRTX Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 29,923 shares — an estimated $13M sold.

Cubist Systematic Strategies first reported a position in VRTX in Q2 2014 and held it in 39 quarters. The position peaked at $29.4M in Q1 2021. 1,546 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

Cubist Systematic Strategies reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Cubist Systematic Strategies sold 29,923 Vertex Pharmaceuticals shares in Q2 2024, an estimated $13M.
Cubist Systematic Strategies first reported a position in Vertex Pharmaceuticals in Q2 2014 and held it in 39 quarters.
Cubist Systematic Strategies's Vertex Pharmaceuticals position peaked at $29.4M in Q1 2021.
1,546 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.